MicroPort Endovascular Officially Opened

March 13, 2013, Shanghai -- MicroPort Endovascular (Shanghai) Co., Ltd. (hereinafter referred to as MicroPort Endovascular) located in Shanghai International Medical Zone officially opened its door to the public.

Cooperation, Innovation and Transition: The New Focus of CIT and MicroPort

The 11th annual scientific sessions of China Interventional Therapeutics (CIT2013) in partnership with TCT was held on Wednesday, March 20 through Saturday, March 23, 2013 at the China National Convention Center (CNCC).

Dr. Martin B. Leon Visiting MicroPort

March 25th, 2013 -- after the 11th annual scientific sessions of China Interventional Therapeutics (CIT2013) ended in Beijing, Dr. Martin B. Leon, the Chairman of CIT and a professor of medical center of University of Columbia, along with secretary of CIT and Mr. Bo Xu, director of Fuwai cardiovascular hospital, visited the headquarter of MicroPort.

Two Occluder Devices Received SFDA Re-registrations

MicroPort Scientific Corporation (HK: 00853) announced that one of its subsidiaries, Dongguan Kewei Medical, has received SFDA re-registrations on two occluder devices.
MicroPort Endovascular Officially Opened

March 13, 2013, Shanghai -- MicroPort Endovascular (Shanghai) Co., Ltd. (hereinafter referred to as MicroPort Endovascular) located in Shanghai International Medical Zone officially opened its door to the public. MicroPort Endovascular is a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Limited. A grand ceremony was held in front of its building and Ms. Yan Zhang, Group President; Qiyi Luo, Group Chief Technology Officer, Ms. Bo Pan, Group Chief Marketing Officer and Mr. Kongrong Pan, Group Vice President of Supply Chain Manager attended the ceremony.

Ms. Zhenghua Miao, General Manager, addressed the ceremony, encouraging all employees to work hard in contributing toward the future success of this new enterprise and development of the MicroPort Endovascular.

MicroPort Endovascular has a dedicated and committed team that includes Dr. Zhonghua Li, an oversea returnee and General Manager of MicroPort Endovascular. In the next 5 years, this team will lead MicroPort Endovascular to a more prosperous future.

Currently, MicroPort Endovascular has following products. Aegis-B Bifurcated Stent-Graft System for the endovascular treatment of AAA is designed as a unique unibody, made of high elastic cobalt chromium alloy and low porosity ePTFE graft. Hercules Stent-Graft System is intended to treat fusiform or saccular aneurysms/penetrating ulcers in thoracic aorta. The domestic market share is around 30%. In addition, Hercules has received various awards for its innovative features from city and local government.

Cronus Surgical Stent Graft is modified vascular graft prosthesis, specifically designed for one-stage repair in complex thoracic aortic disease through median sternotomy in an elephant trunk like fashion. Cronus Surgical Stent Graft achieves the combination of surgical and interventional approaches while avoiding the weaknesses associated with the individual method. The encouraging low prevalence of morbidity and mortality has made the surgery for complex thoracic aortic disease more convenient and achievable.

Castor Branched Stent Graft is designed for complex thoracic aortic disease involving branched arteries, which has clearly allowed for the application of interventions in the descending aorta as well as the visceral aorta. Crownus Peripheral Stent is for the treatment of peripheral artery stenosis, which is the only domestic peripheral product brand in China. In addition, other various projects are in the research and development phases.

MicroPort Endovascular has a highly dedicated and committed global leadership team, and so far has received a number of domestic and foreign patents. Its primary focus is on the development, manufacture, and marketing of the interventional medical devices for the treatment of heart, brain, peripheral vascular and endovascular-related diseases. As one of important group members in "10+5 United Fleets of MicroPort", it will serve an important role and deliver a steady cadence of compelling product innovations into the market.

Cooperation, Innovation and Transition: The New Focus of CIT and MicroPort

The 11th annual scientific sessions of China Interventional Therapeutics (CIT2013) in partnership with TCT was held on Wednesday, March 20 through Saturday, March 23, 2013 at the China National Convention Center (CNCC). As CIT enters its second decade, a new concept and idealism has slowly emerged beyond the conventional academic exchanges and technical training. Now, the new abbreviation of CIT stands for C-Cooperation, I-Innovation, T-transition and this new interpretation underlies the
main theme for this year's event. Dr. Zhaohua Chang, CEO of the Shanghai MicroPort Medical (Group) Co., Ltd. ("the Group") and Qiyi Luo, CTO of the Group, attended both forums: Featured Lecture and Innovation in Vascular Therapies.

The second generation drug-eluting stent Firebird2™ Rapamycin-Eluting CoCr Coronary Stent (the "Firebird2™"), has been well received among cardiologist community. Professor Yan Li from Fourth Military Medical University presented the 18-month clinical follow-up results of FIRE2-DIABETES study, Firebird2™ in the treatment of complex lesions in diabetic patients, which is supervised by Professor Haichang Wang. Compared with foreign-imported DES products, the Major Adverse Cardiac Events (MACE) and Target Lesion Revascularization (TLR) rate were comparable, the safety and efficacy of Firebird2™ were reconfirmed in diabetic patients.

On March 22, the Luncheon Symposium titled "Firebird2™ Clinical Review", chaired by Professor Yong Huo, Costantino R. Costantini, Professor Guosheng Fu, Professor Lang Li and other experts include Feng Zhang, Alfredo E. Rodriguez, and Muhammad Munawar. The 3-year follow-up results from FOCUS study and clinical endpoint data from Argentinean centers were discussed by the panel members. The safety and efficacy of Firebird2™ were consistently proven in the large scale registry study and the important data from randomized controlled trial in complex lesions will be greatly beneficial to patients and cardiologists.

During the last year TCT2012, the exciting clinical data from TARGET trials for our third generation drug-eluting stent, the Firehawk® Rapamycin Target Eluting Coronary Stent (the "Firehawk®"), independently developed by the Group, has been released to the public. During the CIT2013 special Luncheon Symposium on March 21, the study's principal investigator Dr. Runlin Gao, updated TARGET series study of the one-year follow-up clinical results. Martin B. Leon, Professor Wenyi Guo, Professor Hongbing Yan, Runlin Gao actively participated in the discussion forum titled "New Firehawk® DES Platforms: Looking to the Future" sponsored by the Group. All the specialists engaged in a lively discussion on the Firehawk® Target study.

On March 22, Dr. Alexandra Lansky formally announced the combined clinical result from Target I and II based on the data for the primary endpoint of TLF to 12-month target value (OPC, Objective Performance Criteria). There were a total of 1,007 patents enrolled in both trials. The TLF for Firehawk is 3.9% which is lower than the target value of 9%. The major clinical endpoints target was met. To date, all patient enrollments and data collection required for the pre-marketing of Firehawk® have been achieved.

The market size in China represents 400 billion RMB in medical device industry and the annual growth rates reaches as high as 20%. There is a strong fundamental with demographics and global opportunities. As China's population continues to age, cardiovascular disease has risen as one of the greatest threats to individual health. Currently, approximately 230 million people in the country suffer from cardiovascular disease and approximately 3.5 million people die from it each year. According to data released by the cardiovascular interventional diagnosis and treatment management information network of China's Ministry of Health, in 2011 there were more than 330,000 people receiving coronary artery intervention treatment in China. However, compared with developed countries, the penetration in China's operation rate in cardiovascular interventional therapy is still relatively low.

"The DNA of the company, the culture of the company is expressed with our tagline, Where the Patient Always Comes First." Dr. Zhaohua Chang, CEO of the Group said, “A highly dedicated and committed global leadership team is bringing a real zeal for our product portfolio. Our effort on delivering a steady cadence of
compelling product innovations to the market really speaks to what we believe. We truly believe that the innovations and products that we have, have a significant impact on patients’ lives. We will continuously add to our unique and clinically differentiated portfolio and offer best yet affordable products to the market. In addition, we will maintain our leadership in Coronary Artery Disease field with Firebird™ and Firebird2™ as we did in the past 8 years. The outstanding clinical results published on CIT2013 for our third generation drug-eluting stent device Firehawk® will bring meaningful clinical advances over the current generation of products and position the Group to further capture growth in the market.

Dr. Martin B. Leon Visiting MicroPort

March 25th, 2013 -- after the 11th annual scientific sessions of China Interventional Therapeutics (CIT2013) ended in Beijing, Dr. Martin B. Leon, the Chairman of CIT and a professor of medical center of University of Columbia, along with secretary of CIT and Mr. Bo Xu, director of Fuwai cardiovascular hospital, visited the headquarter of MicroPort. Dr. Zhaohua Chang, the Chairman & CEO of MicroPort and other top managements of the company joined the grand reception.

As one of most world-renowned cardiologists and interventional therapy experts, Dr. Martin B. Leon has been doing research on Cardiovascular Disease (CVD) for more than ten years in National Institution of Health (NIH) and was then engaged in clinical research in medical center of Georgetown University. Dr. Martin B. Leon is also a professor of medical school in University of Columbia and the director of heart disease research foundation. Last year during the TCT meeting, Dr. Martin B. Leon, the principal co-investigator of TARGET clinical trial, presented the latest primary endpoint data of Firehawk® TARGET I. In CIT2013, he was also invited as the honored guest to participate in the discussion on the result from TARGET clinical study for Firehawk®.

Accompanied by Mr. Qiyi Luo, Chief Technology Officer of MicroPort, Dr. Martin B. Leon visited the exhibition room, manufacturing area and TC testing laboratory of the company. After the visit, Dr. Martin B. Leon expressed his strong impression about MicroPort. "This is my first trip to MicroPort," Said Dr. Martin B. Leon. "I used to think the most important technology developments with interventional products, particularly in the field of drug-eluting stent, were made in the United States; however, now I am seeing a lot of technological advancements were being achieved outside of the United States. Those advancements have novel properties in which not only competitive, but may actually represents the next generation of new devices. MicroPort has the potential to become the next global leader in the medical device industry."

Two Occluder Devices
Received SFDA Re-registrations

MicroPort Scientific Corporation (HK: 00853) announced that one of its subsidiaries, Dongguan Kewei Medical, has received SFDA re-registrations on two occluder devices: duct occluder (SFDA, 2013 No. 3770019) and atrial septal defect occluder (SFDA, 2013 No.3771706). These approvals again demonstrated MicroPort’s commitment to improving patient quality of life through continuous innovation in minimally invasive medicine.

The septal occluder device is a transcatheter closure device used to treat atrial septal defect (ASD). It consists of Nitinol wire mesh discs filled with alloy grid and 316L stainless steel and polyester film sterilized by ethylene oxide. The device blocks a hole in the wall of a heart and is designed with an umbrella-type design which is folded up until the catheter arrives at the area of the defect in the heart. Once in place the occluder is unfolded on both sides of
the defect so that pressure from both sides keeps it in place.

According to the statistics, the potential patient population in China with congenital heart diseases has reached 2 million and increases at the rate of 200,000 annually. Prior to the advent of percutaneous techniques, surgical closure was the only treatment option for an ASD, regardless of the type of defect. The introduction of MIS with occcluder provided patients with a less-invasive alternative to surgery and also improves quality of life.